Showing results (251-260 of 286) with videos related to
Sort By:
Pageof 29
Journal of Translational Medicine|September 4, 2022
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Christian Blank, et al.Journal of Translational Medicine|July 20, 2023
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022)Paolo A Ascierto, Antonio Avallone, Carlo Bifulco, et al.Journal for Immunotherapy of Cancer|January 5, 2023
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 studyJason Chesney, Karl D Lewis, Harriet Kluger, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2019
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609Ahmad A Tarhini, Sandra J Lee, F Stephen Hodi, et al.Lancet (London, England)|July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialCaroline Robert, Antoni Ribas, Jedd D Wolchok, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibGeorgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.The Lancet. Oncology|April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.The New England Journal of Medicine|June 4, 2013
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanomaOmid Hamid, Caroline Robert, Adil Daud, et al.The New England Journal of Medicine|October 9, 2016
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant TherapyAlexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.The New England Journal of Medicine|April 21, 2015
Pembrolizumab for the treatment of non-small-cell lung cancerEdward B Garon, Naiyer A Rizvi, Rina Hui, et al.Pageof 29